Strategies And Vectors For Gene Therapy: Its Prospective Therapeutic Attributes Against Restenosis 871-878
Dr. Khanna A ,Medical Genetics, MD/PhD Research Fellow , IMT University of Tampere, Tampere,Finland. E-mail: email@example.com
Gene therapy is seen as one of the upcoming technologies not only against diseases which have monogenetic etiology, but also against complex diseases such as cancer and cardiovascular disorders. Amongst the cardiovascular disorders, restenosis is one of many disorders which has seen a major increase in the clinical trials, using gene therapy, in recent years. Restenosis, which is simply reoccurrence of stenosis, is seen mainly post surgically in an artery or blood vessel which had been unblocked. Importantly, even though stents have been introduced to prevent restenosis to occur post surgically, the effect seems to be limited to decreasing the statistical rate , and restenosis still persists as a problem for which a definite solution or remedy, acting on the very roots of its pathogenesis, is the need of the hour. Gene therapy, transfer of a healthy gene for curing a disorder, seems to a promising modality for the purpose. To meet this end a definite strategy, an appropriate vector and target for efficient and persistent expression of the healthy gene in the desired or localized area, is what will make gene therapy against restenosis more effective.